Effectiveness of the Dader Method for Pharmaceutical Care on Patients with Bipolar I Disorder: Results from the EMDADER-TAB Study

Salazar-Ospina, Andrea; Amariles, Pedro; García, Jaime Alejandro Hincapié; González-Avendaño, Sebastián; Benjumea, Dora; Faus, María José; Rodríguez, L. F.

doi:10.18553/jmcp.2017.23.1.74

Cited by 16 publications

(18 citation statements)

References 29 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…14 In comparison with the standard care, pharmaceutical care provides a reduction in the number of hospitalizations and emergency visits not only in patients with depression, but also in patients with bipolar disorder. 15 Rubio-Valera et al 9 found a probability of 0.71-0.75 for community pharmacy intervention vs usual care in depressed patients initiating treatment in terms of improved adherence level and Quality Adjusted Life Years (QALYs) to be cost-effective.…”

Section: Introductionmentioning

confidence: 99%

<p>The Potential Role of the Pharmacist in Supporting Patients with Depression – A Literature-Based Point of View</p>

Kamusheva¹,

Ignatova²,

Gołda³

et al. 2020

IPRP

View full text Add to dashboard Cite

Objective: The current article is aimed at identifying the best practice for counseling around depression in community and outpatient pharmacies, resulting in a draft guideline, proposing key steps and an algorithm for integration of community pharmacists into care for patients with depression. Methods: A literature review was performed followed by a detailed analysis, for the purpose of creation a short draft document used as a basis for creation of a guideline for pharmaceutical care for patients with depression. The technological scheme PRISMA flow diagram was applied. The paper is based on current knowledge, taking into consideration already published articles, guidelines, and recommendations about pharmaceutical care for patients with depression, giving a basis for further studies. Results: This paper includes two main sections: 1) depressiona short description of the main symptoms, risk factors and pharmacotherapy guidelines available in Bulgaria important for the purposes of ensuring qualitative community-based pharmaceutical care; and 2) the pharmacists' role in providing high-quality carethe main aspects of pharmaceutical care for patients with depression with specific examples. Conclusion: The involvement of pharmacists in supporting depressive patients is crucial taking into account the specific characteristics of the pharmacological treatment: delayed onset of clinical results, risks in case of sudden pharmacotherapy abruption without physician consultation, multiple adverse drug reactions and drug-drug, drug-food and drugalcohol interactions, etc. The current article could also be used as an initial document for creating a methodological guideline for providing pharmaceutical care services for patients with depression.

show abstract

Section: Introductionmentioning

confidence: 99%

<p>The Potential Role of the Pharmacist in Supporting Patients with Depression – A Literature-Based Point of View</p>

Kamusheva¹,

Ignatova²,

Gołda³

et al. 2020

IPRP

View full text Add to dashboard Cite

show abstract

“…30,38,39,68 Outpatients in primary care, general mental health, and specialty clinics have improved medication safety (eg, reduction in anticholinergic burden, improved medication appropriateness) and reach therapeutic goals (eg, symptom reduction, fewer hospitalizations) at a higher rate when a pharmacist who is focused on CNS medications contributes to their care. 47,49,52,54,60,64,65 Patients filling prescriptions in community pharmacies have better access to long-acting injectable antipsychotic medications and increased medication adherence and are more satisfied with their medications when receiving pharmacist-delivered, psychiatry-focused interventions. [83][84][85][86] Patients seeking care for SUD experience increased access to buprenorphine-naloxone and naloxone, both life-saving medications, when a psychiatric pharmacist is involved in the SUD care setting.…”

Section: Resultsmentioning

confidence: 99%

Impact of pharmacists on outcomes for patients with psychiatric or neurologic disorders

Werremeyer

Bostwick

Cobb³

et al. 2020

Mental Health Clinician

View full text Add to dashboard Cite

Introduction Psychiatric and neurologic illnesses are highly prevalent and are often suboptimally treated. A 2015 review highlighted the value of psychiatric pharmacists in improving medication-related outcomes. There is a need to describe areas of expansion and strengthened evidence regarding pharmacist practice and patient care impact in psychiatric and neurologic settings since 2015. Methods A systematic search of literature published from January 2014 to June 2019 was conducted. Publications describing patient-level outcome results associated with pharmacist provision of care in a psychiatric/neurologic setting and/or in relation to central nervous system (CNS) medications were included. Results A total of 64 publications were included. There was significant heterogeneity of published study methods and data, prohibiting meta-analysis. Pharmacists practicing across a wide variety of health care settings with focus on CNS medication management significantly improved patient-level outcomes, such as medication adherence, disease control, and avoidance of hospitalization. The most common practice approach associated with significant improvement in patient-level outcomes was incorporation of psychiatric pharmacist input into the interprofessional health care team. Discussion Pharmacists who focus on psychiatric and neurologic disease improve outcomes for patients with these conditions. This is important in the current health care environment as most patients with psychiatric or neurologic conditions continue to have unmet needs. Additional studies designed to measure pharmacists' impact on patient-level outcomes are encouraged to strengthen these findings.

show abstract

“…To our knowledge, no previous randomized controlled trials exist that were designed to evaluate the effect of a clinical pharmacy practice model (CPPM) on the incidence of medication errors (patient safety), and thus, most of these strategies are based on expert recommendations and descriptive studies [8,28]. In Colombia, the first and only related RCT, Effectiveness of a Method for Pharmaceutical Care in outpatients with Bipolar disorder, showed the risk of hospitalizations and emergencies was lower for the intervention group [29]. This study is the first stepped-wedge controlled trial designed to assess the effect of the clinical pharmacy practice model on the incidence of medication error in hospitalized patients.…”

Section: Discussionmentioning

confidence: 99%

Effect and associated factors of a clinical pharmacy model in the incidence of medication errors (EACPharModel) in the Hospital Pablo Tobón Uribe: study protocol for a stepped wedge randomized controlled trial (NCT03338725)

Granados

Salazar-Ospina

Aguirre

et al. 2020

Trials

View full text Add to dashboard Cite

Background: According to WHO, medication error (ME) is a subject that requires attention at all levels of care to reduce severe and preventable damage related to medication use. Clinical pharmacy practice standards have been proposed around the world so that the pharmacist, as part of a multidisciplinary health team, can help improve patient safety; however, further evidence derived from adequate studies is needed to demonstrate this. This study aims to assess the effect of a clinical pharmacy practice model (CPPM) in preventing MEs associated with the medication use process. Methods: A prospective, stepped-wedge, cluster-randomized, controlled trial with a duration of 14 months will be performed to compare the effect of a CPPM along with the usual care process of patients in the Pablo Tobón Uribe Hospital (Medellin, Colombia). The study is designed as a cluster-randomized controlled trial, involving five hospital wards (clusters) and 720 patients. Medical wards are allocated to interventions using a stepped-wedge design. Clusters are initially assigned to the control group. After a 2-month observation period, hospital clusters were randomly allocated to the intervention group. Study outcomes will be assessed at baseline and at 2, 4, 6, 8, 10, and 12 months after randomization. The primary outcome will be to assess the effect of a CPPM on the incidence of medication errors associated with the medication use process. Drug-related problems and factors that contribute to the occurrence of MEs will be assessed as secondary outcomes. Statistical analyses will be performed using a mixed model, with the treatment group and time as fixed effects and the clustering structure as a random effect. Statistical analysis will be performed using Pearson chi-square tests and Student's t-tests, and a P value < 0.05 will be considered statistically significant.

show abstract

Effectiveness of the Dader Method for Pharmaceutical Care on Patients with Bipolar I Disorder: Results from the EMDADER-TAB Study

Cited by 16 publications

References 29 publications

<p>The Potential Role of the Pharmacist in Supporting Patients with Depression – A Literature-Based Point of View</p>

<p>The Potential Role of the Pharmacist in Supporting Patients with Depression – A Literature-Based Point of View</p>

Impact of pharmacists on outcomes for patients with psychiatric or neurologic disorders

Effect and associated factors of a clinical pharmacy model in the incidence of medication errors (EACPharModel) in the Hospital Pablo Tobón Uribe: study protocol for a stepped wedge randomized controlled trial (NCT03338725)

Contact Info

Product

Resources

About